Cargando…

Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States

Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehde, Dawn M., Roberts, Michelle K., Herring, Tracy E., Alschuler, Kevin N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825851/
https://www.ncbi.nlm.nih.gov/pubmed/33508570
http://dx.doi.org/10.1016/j.msard.2021.102788
_version_ 1783640404589019136
author Ehde, Dawn M.
Roberts, Michelle K.
Herring, Tracy E.
Alschuler, Kevin N.
author_facet Ehde, Dawn M.
Roberts, Michelle K.
Herring, Tracy E.
Alschuler, Kevin N.
author_sort Ehde, Dawn M.
collection PubMed
description Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness. Methods: Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources. Results: Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness. Conclusion: Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available.
format Online
Article
Text
id pubmed-7825851
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78258512021-01-25 Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States Ehde, Dawn M. Roberts, Michelle K. Herring, Tracy E. Alschuler, Kevin N. Mult Scler Relat Disord Article Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness. Methods: Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources. Results: Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness. Conclusion: Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available. Elsevier B.V. 2021-04 2021-01-22 /pmc/articles/PMC7825851/ /pubmed/33508570 http://dx.doi.org/10.1016/j.msard.2021.102788 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ehde, Dawn M.
Roberts, Michelle K.
Herring, Tracy E.
Alschuler, Kevin N.
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
title Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
title_full Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
title_fullStr Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
title_full_unstemmed Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
title_short Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
title_sort willingness to obtain covid-19 vaccination in adults with multiple sclerosis in the united states
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825851/
https://www.ncbi.nlm.nih.gov/pubmed/33508570
http://dx.doi.org/10.1016/j.msard.2021.102788
work_keys_str_mv AT ehdedawnm willingnesstoobtaincovid19vaccinationinadultswithmultiplesclerosisintheunitedstates
AT robertsmichellek willingnesstoobtaincovid19vaccinationinadultswithmultiplesclerosisintheunitedstates
AT herringtracye willingnesstoobtaincovid19vaccinationinadultswithmultiplesclerosisintheunitedstates
AT alschulerkevinn willingnesstoobtaincovid19vaccinationinadultswithmultiplesclerosisintheunitedstates